Christopher C Dvorak

List of Publications by Year
in descending order

267	8,276	46918 47	62479 80
papers	citations	h-index	g-index

276	276	276	8655
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Transplantation Outcomes for Severe Combined Immunodeficiency, 2000â€“2009. New England Journal of Medicine, 2014, 371, 434-446.	13.9	594
2	Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: The Primary Immune Deficiency Treatment Consortium experience. Journal of Allergy and Clinical Immunology, 2014, 133, 1092-1098.	1.5	301
3	Pediatric Invasive Aspergillosis: A Multicenter Retrospective Analysis of 139 Contemporary Cases. Pediatrics, 2008, 121, e1286-e1294.	1.0	283
4	Clinical outcome in IL-10â€“ and IL-10 receptorâ€“deficient patients with or without hematopoietic stem cell transplantation. Journal of Allergy and Clinical Immunology, 2013, 131, 825-830.e9.	1.5	236
5	Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. Journal of Allergy and Clinical Immunology, 2018, 141, 1036-1049.e5.	1.5	233
6	Immune reconstitution and survival of 100 SCID patients postâ€“hematopoietic cell transplant: a PIDTC natural history study. Blood, 2017, 130, 2718-2727.	0.6	212
7	Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematology,the, 2016, 3, e526-e536.	2.2	197
8	Metagenomic Sequencing Detects Respiratory Pathogens in Hematopoietic Cellular Transplant Patients. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 524-528.	2.5	187
9	The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis. Haematologica, 2015, 100, 978-988.	1.7	161
10	Outcomes after Hematopoietic Stem Cell Transplantation for Children with I-Cell Disease. Biology of Blood and Marrow Transplantation, 2014, 20, 1847-1851.	2.0	150
11	SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. Blood, 2014, 123, 281-289.	0.6	150
12	Results From a Prospective, International, Epidemiologic Study of Invasive Candidiasis in Children and Neonates. Pediatric Infectious Disease Journal, 2012, 31, 1252-1257.	1.1	148
13	Newborn Screening for Severe Combined Immunodeficiency and T-cell Lymphopenia in California, 2010â€“2017. Pediatrics, 2019, 143, .	1.0	148
14	Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation. JAMA - Journal of the American Medical Association, 2018, 320, 995.	3.8	136
15	SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. Blood, 2018, 132, 1737-1749.	0.6	128
16	Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2005, 36, 621-629.	1.3	117
17	Pulmonary Metagenomic Sequencing Suggests Missed Infections in Immunocompromised Children. Clinical Infectious Diseases, 2019, 68, 1847-1855.	2.9	112
18	Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation. Journal of Allergy and Clinical Immunology, 2017, 139, 1282-1292.	1.5	107

#	Article	IF	Citations
19	Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies. Leukemia, 2015, 29, 1754-1762.	3.3	103
20	The Natural History of Children with Severe Combined Immunodeficiency: Baseline Features of the First Fifty Patients of the Primary Immune Deficiency Treatment Consortium Prospective Study 6901. Journal of Clinical Immunology, 2013, 33, 1156-1164.	2.0	100
21	Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia. Blood, 2014, 124, 2487-2497.	0.6	98
22	Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome. Journal of Allergy and Clinical Immunology, 2017, 139, 1046-1049.	1.5	90
23	NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Endocrine Challengesâ€"Thyroid Dysfunction, Growth Impairment, Bone Health, & Reproductive Risks. Biology of Blood and Marrow Transplantation, 2011, 17, 1725-1738.	2.0	89
24	Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Advances, 2018, 2, 2550-2553.	2.5	88
25	Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. Blood, 2020, 135, 2094-2105.	0.6	87
26	A Prospective, International Cohort Study of Invasive Mold Infections in Children. Journal of the Pediatric Infectious Diseases Society, 2015, 4, 313-322.	0.6	86
27	National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: The Need for Pediatric-Specific Long-Term Follow-up Guidelines. Biology of Blood and Marrow Transplantation, 2012, 18, 334-347.	2.0	82
28	Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment ofÂsevere combined immunodeficiency. Journal of Allergy and Clinical Immunology, 2014, 134, 935-943.e15.	1.5	82
29	Plasma angiopoietin-2 outperforms other markers of endothelial injury in prognosticating pediatric ARDS mortality. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 310, L224-L231.	1.3	74
30	Transplant-Associated Thrombotic Microangiopathy in Pediatric Hematopoietic Cell Transplant Recipients: A Practical Approach to Diagnosis and Management. Frontiers in Pediatrics, 2019, 7, 133.	0.9	74
31	Treatment of infants identified as having severe combined immunodeficiency by means of newborn screening. Journal of Allergy and Clinical Immunology, 2017, 139, 733-742.	1.5	73
32	Effect of Weight and Maturation on Busulfan Clearance in Infants and Small Children Undergoing Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1608-1614.	2.0	69
33	Classification of treatment-related mortality in children with cancer: a systematic assessment. Lancet Oncology, The, 2015, 16, e604-e610.	5.1	69
34	The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. Bone Marrow Transplantation, 2016, 51, 573-580.	1.3	68
35	Population Pharmacokinetics of Busulfan in Pediatric and Young Adult Patients Undergoing Hematopoietic Cell Transplant. Therapeutic Drug Monitoring, 2015, 37, 236-245.	1.0	67
36	Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia. JAMA - Journal of the American Medical Association, 2019, 322, 1673.	3.8	67

#	Article	IF	Citations
37	Hematopoietic stem cell transplantation for primary immunodeficiency disease. Bone Marrow Transplantation, 2008, 41, 119-126.	1.3	66
38	Primary Immune Deficiency Treatment Consortium (PIDTC) report. Journal of Allergy and Clinical Immunology, 2014, 133, 335-347.e11.	1.5	65
39	New Insights Into Multicenter PICU Mortality Among Pediatric Hematopoietic Stem Cell Transplant Patients*. Critical Care Medicine, 2015, 43, 1986-1994.	0.4	65
40	The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018). Journal of Allergy and Clinical Immunology, 2019, 143, 405-407.	1.5	64
41	TNF-Receptor Inhibitor Therapy for the Treatment of Children with Idiopathic Pneumonia Syndrome. A Joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521). Biology of Blood and Marrow Transplantation, 2015, 21, 67-73.	2.0	62
42	Hematopoietic stem cell transplantation for CD40 ligand deficiency: Results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study. Journal of Allergy and Clinical Immunology, 2019, 143, 2238-2253.	1.5	60
43	Radiosensitive Severe Combined Immunodeficiency Disease. Immunology and Allergy Clinics of North America, 2010, 30, 125-142.	0.7	59
44	Incidence, Risk Factors for and Outcomes of Transplantâ€Associated Thrombotic Microangiopathy. British Journal of Haematology, 2020, 189, 1171-1181.	1.2	58
45	Antifungal prophylaxis in pediatric hematology/oncology: New choices & new data. Pediatric Blood and Cancer, 2012, 59, 21-26.	0.8	57
46	Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. Frontiers in Immunology, 2020, 11, 239.	2.2	57
47	Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs. Bone Marrow Transplantation, 2010, 45, 1602-1606.	1.3	55
48	Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-Host Disease without Delaying Immune Reconstitution. Biology of Blood and Marrow Transplantation, 2012, 18, 1656-1663.	2.0	51
49	Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders. Bone Marrow Transplantation, 2008, 42, 83-91.	1.3	48
50	Related and unrelated donor transplantation for Î²-thalassemia major: results of an international survey. Blood Advances, 2019, 3, 2562-2570.	2.5	48
51	Megadose CD34 + Cell Grafts Improve Recovery of T Cell Engraftment but not B Cell Immunity in Patients with Severe Combined Immunodeficiency Disease Undergoing Haplocompatible Nonmyeloablative Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 1125-1133.	2.0	47
52	Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2019, 54, 1254-1265.	1.3	47
53	A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant. Blood Advances, 2021, 5, 1-11.	2.5	46
54	Pathological evidence of Wolman's disease following hematopoietic stem cell transplantation despite correction of lysosomal acid lipase activity. Bone Marrow Transplantation, 2009, 44, 449-450.	1.3	43

#	Article	IF	Citations
55	Juvenile Myelomonocytic Leukemia: Molecular Pathogenesis Informs Current Approaches to Therapy and Hematopoietic Cell Transplantation. Frontiers in Pediatrics, 2014, 2, 25.	0.9	43
56	Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. Haematologica, 2015, 100, 17-22.	1.7	43
57	Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. Journal of Clinical Immunology, 2019, 39, 653-667.	2.0	41
58	Bloodstream Infection Due to Vancomycin-resistant Enterococcus Is Associated With Increased Mortality After Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study. Clinical Infectious Diseases, 2019, 69, 1771-1779.	2.9	41
59	Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia. Blood, 2012, 119, 6155-6161.	0.6	40
60	Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injuryâ€“Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. JAMA Network Open, 2020, 3, e1918668.	2.8	40
61	B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. Blood, 2018, 131, 2967-2977.	0.6	37
62	Toxicity-Free Hematopoietic Stem Cell Engraftment Achieved with Anti-CD117 Monoclonal Antibody Conditioning. Biology of Blood and Marrow Transplantation, 2019, 25, S92.	2.0	37
63	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Advances, 2019, 3, 3123-3131.	2.5	37
64	Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers. Journal of Clinical Immunology, 2021, 41, 38-50.	2.0	36
65	Prevention of bacterial infection in pediatric oncology: What do we know, what can we learn?. Pediatric Blood and Cancer, 2012, 59, 16-20.	0.8	35
66	Early Plasma Matrix Metalloproteinase Profiles. A Novel Pathway in Pediatric Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 181-189.	2.5	35
67	Hematopoietic Cell Transplant and Use of Massage for Improved Symptom Management: Results from a Pilot Randomized Control Trial. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-9.	0.5	34
68	International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome. Journal of Allergy and Clinical Immunology, 2022, 149, 410-421.e7.	1.5	34
69	Chimerism-Based Pre-Emptive Immunotherapy with Fast Withdrawal of Immunosuppression and Donor Lymphocyte Infusions after Allogeneic Stem Cell Transplantation for Pediatric Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2015, 21, 729-737.	2.0	33
70	Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients. Biology of Blood and Marrow Transplantation, 2017, 23, 1701-1713.	2.0	32
71	Hematopoietic Stem Cell Transplant for Pediatric Acute Promyelocytic Leukemia. Biology of Blood and Marrow Transplantation, 2008, 14, 824-830.	2.0	31
72	Haploidentical related-donor hematopoietic cell transplantation in children using megadoses of CliniMACs-selected CD34+ cells and a fixed CD3+ dose. Bone Marrow Transplantation, 2013, 48, 508-513.	1.3	31

#	Article	IF	Citations
73	Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation. Blood, 2014, 123, 3504-3511.	0.6	31
74	A Multicenter Study of Bacterial Blood Stream Infections in Pediatric Allogeneic Hematopoietic Cell Transplantation Recipients: The Role of Acute Gastrointestinal Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 642-647.	2.0	31
75	Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study. Bone Marrow Transplantation, 2017, 52, 270-278.	1.3	31
76	Transplacental maternal engraftment and posttransplantation graft-versus-host disease in children with severe combined immunodeficiency. Journal of Allergy and Clinical Immunology, 2017, 139, 628-633.e10.	1.5	30
77	Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries. Biology of Blood and Marrow Transplantation, 2020, 26, 333-342.	2.0	30
78	Massage for Children Undergoing Hematopoietic Cell Transplantation: A Qualitative Report. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-9.	0.5	29
79	Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. Biology of Blood and Marrow Transplantation, 2018, 24, 2040-2046.	2.0	29
80	Maternal T-cell Engraftment Associated With Severe Hemophagocytosis of the Bone Marrow in Untreated X-linked Severe Combined Immunodeficiency. Journal of Pediatric Hematology/Oncology, 2008, 30, 396-400.	0.3	27
81	Consensus Report by Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees: Supportive Care Guidelines for Management of Veno-Occlusive Disease in Children and Adolescents, Part 1: Focus on Investigations, Prophylaxis, and Specific Treatment. Biology of Blood and Marrow Transplantation, 2017, 23, 1817-1825.	2.0	27
82	Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. Biology of Blood and Marrow Transplantation, 2019, 25, 301-306.	2.0	27
83	Fusion driven JMML: a novel CCDC88Câ€“FLT3 fusion responsive to sorafenib identified by RNA sequencing. Leukemia, 2020, 34, 662-666.	3.3	27
84	Hematopoietic Stem Cell Transplantation for Severe Combined Immunodeficiency. Current Pediatrics Reports, 2015, 3, 1-10.	1.7	26
85	Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatric Blood and Cancer, 2018, 65, e27034.	0.8	26
86	Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2015, 21, 2154-2159.	2.0	25
87	Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2018, 53, 1278-1287.	1.3	25
88	Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, 1273-1277.	2.0	24
89	Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population. Frontiers in Pharmacology, 2020, 11, 888.	1.6	24
90	The Safety of Olanzapine in Young Children: A Systematic Review and Meta-Analysis. Drug Safety, 2014, 37, 791-804.	1.4	23

#	Article	IF	Citations
91	Low Exposure Busulfan Conditioning to Achieve Sufficient Multilineage Chimerism in Patients with Severe Combined Immunodeficiency. Biology of Blood and Marrow Transplantation, 2019, 25, 1355-1362.	2.0	22
92	The impact of total body irradiationâ€based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Pediatric Blood and Cancer, 2020, 67, e28079.	0.8	22
93	Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. Blood Advances, 2018, 2, 1198-1206.	2.5	21
94	A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. Blood, 2021, 137, 983-993.	0.6	20
95	Repeat blood cultures in children with persistent fever and neutropenia: Diagnostic and clinical implications. Pediatric Blood and Cancer, 2015, 62, 1421-1426.	0.8	19
96	Reducing Second Gram-Negative Antibiotic Therapy on Pediatric Oncology and Hematopoietic Stem Cell Transplantation Services. Infection Control and Hospital Epidemiology, 2017, 38, 1039-1047.	1.0	19
97	Autoimmune Cytopenias in Pediatric Hematopoietic Cell Transplant Patients. Frontiers in Pediatrics, 2019, 7, 171.	0.9	19
98	A Randomized Trial of Caspofungin vs Triazoles Prophylaxis for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplant. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 417-425.	0.6	19
99	Daratumumab Is Effective in the Treatment of Refractory Post-Transplant Autoimmune Hemolytic Anemia: A Pediatric Case Report. Blood, 2016, 128, 4819-4819.	0.6	19
100	NCI, NHLBI First International Consensus Conference on Late Effects after Pediatric Hematopoietic CellÂTransplantation: State of the Science, FutureÂDirections. Biology of Blood and Marrow Transplantation, 2011, 17, 1424-1427.	2.0	18
101	Multisite external validation of a risk prediction model for the diagnosis of blood stream infections in febrile pediatric oncology patients without severe neutropenia. Cancer, 2017, 123, 3781-3790.	2.0	18
102	The pulmonary metatranscriptome prior to pediatric HCT identifies post-HCT lung injury. Blood, 2021, 137, 1679-1689.	0.6	18
103	Consensus Report by the Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplant Consortium Joint Working Committees on Supportive Care Guidelines for Management of Veno-Occlusive Disease in Children and Adolescents: Part 2â€"Focus on Ascites, Fluid and Electrolytes, Renal, and Transfusion Issues. Biology of Blood and Marrow Transplantation, 2017, 23, 2023-2033.	2.0	17
104	Veno-occlusive disease after high-dose busulfanâ€"melphalan in neuroblastoma. Bone Marrow Transplantation, 2020, 55, 531-537.	1.3	17
105	Short tandem repeat and human leukocyte antigen mutations or losses confound engraftment and typing analysis in hematopoietic stem cell transplants. Human Immunology, 2011, 72, 503-509.	1.2	16
106	Pediatric Hematopoietic Cell Transplant Patients Who Survive Critical Illness Frequently Have Significant but Recoverable Decline in Functional Status. Biology of Blood and Marrow Transplantation, 2018, 24, 330-336.	2.0	16
107	Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders. Journal of Allergy and Clinical Immunology, 2022, 149, 1097-1104.e2.	1.5	16
108	Non-Genotoxic Anti-CD117 Antibody Conditioning Results in Successful Hematopoietic Stem Cell Engraftment in Patients with Severe Combined Immunodeficiency. Blood, 2019, 134, 800-800.	0.6	16

#	Article	IF	Citations
109	Liposomal Amphotericin B Associated With Severe Hyperphosphatemia. Pediatric Infectious Disease Journal, 2008, 27, 77-79.	1.1	15
110	Infrastructure of Fertility Preservation Services for Pediatric Cancer Patients: A Report From the Children's Oncology Group. JCO Oncology Practice, 2022, 18, e325-e333.	1.4	15
111	Children's Oncology Group's 2013 blueprint for research: Stem cell transplantation. Pediatric Blood and Cancer, 2013, 60, 1044-1047.	0.8	14
112	The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, 1251-1257.	2.0	14
113	Juvenile Myelomonocytic Leukemia. Pediatric Clinics of North America, 2015, 62, 95-106.	0.9	14
114	Neurologic eventâ€“free survival demonstrates a benefit for SCID patients diagnosed by newborn screening. Blood Advances, 2017, 1, 1694-1698.	2.5	14
115	Practice pattern changes and improvements in hematopoietic cell transplantation for primary immunodeficiencies. Journal of Allergy and Clinical Immunology, 2018, 142, 2004-2007.	1.5	14
116	Survival Trends in Infants Undergoing Allogeneic Hematopoietic Cell Transplant. JAMA Pediatrics, 2019, 173, e190081.	3.3	14
117	Early Outcome of a Phase I/II Clinical Trial (NCT03538899) of Gene-Corrected Autologous CD34+ Hematopoietic Cells and Low-Exposure Busulfan in Newly Diagnosed Patients with Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID). Biology of Blood and Marrow Transplantation, 2020, 26, S88-S89.	2.0	14
118	Chlorhexidine gluconate bathing in children with cancer or those undergoing hematopoietic stem cell transplantation: A doubleâ€blinded randomized controlled trial from the Children's Oncology Group. Cancer, 2021, 127, 56-66.	2.0	14
119	Prospective Evaluation of Galactomannan and (1â†'3) Î²-<scp>d</scp>-Glucan Assays as Diagnostic Tools for Invasive Fungal Disease in Children, Adolescents, and Young Adults With Acute Myeloid Leukemia Receiving Fungal Prophylaxis. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 864-871.	0.6	14
120	Outcome of Myeloablative Conditioning and Unrelated Donor Hematopoietic Cell Transplantation for Childhood Acute Lymphoblastic Leukemia in Third Remission. Biology of Blood and Marrow Transplantation, 2011, 17, 1833-1840.	2.0	13
121	Simultaneous determination of fludarabine and clofarabine in human plasma by LCâ€“MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 960, 194-199.	1.2	13
122	A trial of plerixafor adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency. Pediatric Transplantation, 2014, 18, 602-608.	0.5	13
123	Safe and Effective Prophylaxis with Bimonthly Intravenous Pentamidine in the Pediatric Hematopoietic Stem Cell Transplant Population. Pediatric Infectious Disease Journal, 2016, 35, 135-141.	1.1	13
124	Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia. Pediatric Blood and Cancer, 2019, 66, e27948.	0.8	13
125	Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma. Biology of Blood and Marrow Transplantation, 2019, 25, 2031-2039.	2.0	13
126	Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. Haematologica, 2019, 104, 844-854.	1.7	13

#	Article	IF	Citations
127	Identifying clinical practice guidelines for the supportive care of children with cancer: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2019, 66, e27471.	0.8	13
128	Juvenile myelomonocytic leukemia in the molecular era: a clinicianâ€™s guide to diagnosis, risk stratification, and treatment. Blood Advances, 2021, 5, 4783-4793.	2.5	13
129	A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in highâ€risk pediatric patients. Pediatric Blood and Cancer, 2022, 69, e29641.	0.8	13
130	Use of intravenous mycophenolate mofetil for graft-versus-host disease prophylaxis in an allogeneic hematopoietic stem cell transplant recipient with an allergic reaction to cyclosporine and tacrolimus. Bone Marrow Transplantation, 2006, 38, 253-254.	1.3	12
131	A trial of alemtuzumab adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency. Pediatric Transplantation, 2014, 18, 609-616.	0.5	12
132	Severe, persistent, and fatal Tâ€cell immunodeficiency following therapy for infantile leukemia. Pediatric Blood and Cancer, 2016, 63, 2046-2049.	0.8	12
133	Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 196-202.	0.6	12
134	Clinical and immunologic outcomes following haplocompatible donor lymphocyte infusions. Bone Marrow Transplantation, 2009, 44, 805-812.	1.3	11
135	Severe Neonatal Congenital Erythropoietic Porphyria. Pediatric Dermatology, 2011, 28, 416-420.	0.5	11
136	Epidemiology and potential preventative measures for viral infections in children with malignancy and those undergoing hematopoietic cell transplantation. Pediatric Blood and Cancer, 2012, 59, 11-15.	0.8	11
137	Chronic norovirus infection in primary immune deficiency disorders: an international case series. Diagnostic Microbiology and Infectious Disease, 2019, 93, 69-73.	0.8	11
138	Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. Biology of Blood and Marrow Transplantation, 2019, 25, 699-711.	2.0	11
139	SAFETY OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN LESS THAN THREE YEARS OF AGE. Pediatric Hematology and Oncology, 2008, 25, 705-722.	0.3	10
140	Primary Graft Failure After Umbilical Cord Blood Transplant Rescued by Parental Haplocompatible Stem Cell Transplantation. Journal of Pediatric Hematology/Oncology, 2009, 31, 300-303.	0.3	10
141	Treatment of Hepatoblastoma With High-dose Chemotherapy and Stem Cell Rescue. Journal of Pediatric Hematology/Oncology, 2014, 36, 362-368.	0.3	10
142	Consensus Report by the Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees on Supportive Care Guidelines for Management of Veno-Occlusive Disease in Children and Adolescents, Part 3: Focus on Cardiorespiratory Dysfunction, Infections, Liver Dysfunction, and Delirium. Biology of Blood and Marrow Transplantation, 2018, 24, 207-218.	2.0	10
143	Burden of illness associated with sinusoidal obstruction syndrome/veno-occlusive disease in patients with hematopoietic stem cell transplantation. Journal of Medical Economics, 2017, 20, 871-883.	1.0	10
144	Reinduction of relapsed acute promyelocytic leukemia with ATRA and low dose antimetabolite-based chemotherapy. Pediatric Blood and Cancer, 2007, 48, 582-585.	0.8	9

#	Article	IF	Citations
145	Development of Herpes Simplex Virus Stomatitis during Receipt of Cidofovir Therapy. Clinical Infectious Diseases, 2009, 49, e92-e95.	2.9	9
146	Reduced Toxicity Conditioning for Nonmalignant Hematopoietic Cell Transplants. Biology of Blood and Marrow Transplantation, 2020, 26, 1646-1654.	2.0	9
147	Practice patterns and incidence of adenovirus infection in allogeneic hematopoietic cell transplant recipients: Multicenter survey of transplant centers in the United States. Transplant Infectious Disease, 2020, 22, e13283.	0.7	9
148	High-dose chemotherapy followed by stem cell rescue for high-risk germ cell tumors: the Stanford experience. Bone Marrow Transplantation, 2009, 43, 547-552.	1.3	8
149	Early mixed chimerismâ€based preemptive immunotherapy in children undergoing allogeneic hematopoietic stem cell transplantation for acute leukemia. Pediatric Blood and Cancer, 2017, 64, e26464.	0.8	8
150	Unconditioned unrelated donor bone marrow transplantation for IL7RÎ±- and Artemis-deficient SCID. Bone Marrow Transplantation, 2017, 52, 1036-1038.	1.3	8
151	Opening Marrow Niches in Patients Undergoing Autologous Hematopoietic Stem Cell Gene Therapy. Hematology/Oncology Clinics of North America, 2017, 31, 809-822.	0.9	8
152	Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis. Blood Advances, 2021, 5, 2106-2114.	2.5	8
153	Poor T-cell receptor Î² repertoire diversity early posttransplant for severe combined immunodeficiency predicts failure of immune reconstitution. Journal of Allergy and Clinical Immunology, 2022, 149, 1113-1119.	1.5	8
154	Hospital resource utilization among patients with sickle cell disease. Journal of Health Care for the Poor and Underserved, 2003, 14, 122-35.	0.4	8
155	Safety of pre-emptive donor lymphocyte infusions (DLI) based on mixed chimerism (MC) in peripheral blood or bone marrow subsets in children undergoing hematopoietic stem cell transplant (HSCT) for hematologic malignancies. Bone Marrow Transplantation, 2017, 52, 1057-1059.	1.3	7
156	Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results. Biology of Blood and Marrow Transplantation, 2019, 25, 955-964.	2.0	7
157	Complications of Transplant for Nonmalignant Disorders: Autoimmune Cytopenias, Opportunistic Infections, and PTLD. Biology of Blood and Marrow Transplantation, 2012, 18, S101-S110.	2.0	6
158	Extracorporeal life support survival in a pediatric hematopoietic cellular transplant recipient with presumed GvHD-related fulminant myocarditis. Bone Marrow Transplantation, 2017, 52, 1330-1333.	1.3	6
159	Population Pharmacokinetics of Clofarabine as Part of Pretransplantation Conditioning in Pediatric Subjects before Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1603-1610.	2.0	6
160	An Interim Evaluation of Systemic F-Ara-a Exposure in Pediatric Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients Using An Optimal Sampling Design. Blood, 2011, 118, 1962-1962.	0.6	6
161	Pulmonary microbiome and gene expression signatures differentiate lung function in pediatric hematopoietic cell transplant candidates. Science Translational Medicine, 2022, 14, eabm8646.	5.8	6
162	Competitive TNF Inhibitor (ETANERCEPT) for the Treatment of Idiopathic Pneumonia Syndrome (IPS) Following Allogeneic Stem Cell Transplantation (SCT). A Joint Pediatric Blood and Marrow Transplant Consortium (PBMTC) and Childrens Oncology Group (COG) Study. Biology of Blood and Marrow Transplantation, 2013, 19, S111-S112.	2.0	5

#	Article	IF	Citations
163	Pulmonary veno-occlusive disease in a pediatric hematopoietic stem cell transplant patient: a cautionary tale. Leukemia and Lymphoma, 2018, 59, 1494-1497.	0.6	5
164	NUP98-NSD1 Driven MDS/MPN in Childhood Masquerading as JMML. Journal of Pediatric Hematology/Oncology, 2021, 43, e808-e811.	0.3	5
165	JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived NaÃ¯ve Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID). Blood, 2021, 138, 554-554.	0.6	5
166	In Utero Stem Cell Transplantation in Patients with Alpha Thalassemia Major: Interim Results of a Phase 1 Clinical Trial. Blood, 2020, 136, 1-1.	0.6	5
167	First Report of Non-Genotoxic Conditioning with JSP191 (anti-CD117) and Hematopoietic Stem Cell Transplantation in a Newly Diagnosed Patient with Severe Combined Immune Deficiency. Blood, 2020, 136, 10-10.	0.6	5
168	The Natural History of Children with Severe Combined Immunodeficiency Disease (SCID): The First Fifty Patients of the Primary Immune Deficiency Treatment Consortium (PIDTC) Prospective Study 6901. Biology of Blood and Marrow Transplantation, 2013, 19, S161-S162.	2.0	4
169	Genotype, Phenotype and T Cell Counts at One Year Predict Survival and Long Term Immune Reconstitution after Transplantation in Severe Combined Immune Deficiency (SCID)â€"The Primary Immune Deficiency Treatment Consortium (PIDTC). Biology of Blood and Marrow Transplantation, 2017, 23, S133-S134.	2.0	4
170	Determination of melphalan in human plasma by UPLCâ€"UV method. Cancer Chemotherapy and Pharmacology, 2019, 83, 905-910.	1.1	4
171	Lower Exposure to Busulfan Allows for Stable Engraftment of Donor Hematopoietic Stem Cells in Children with Mucopolysaccharidosis Type I: A Case Report of Four Patients. International Journal of Molecular Sciences, 2020, 21, 5634.	1.8	4
172	International Retrospective Study of Allogeneic Hematopoietic Cell Transplantation (HCT) for Activated Phosphoinositide 3-Kinase Delta (PI3K) Syndrome. Biology of Blood and Marrow Transplantation, 2020, 26, S14-S15.	2.0	4
173	TA-TMA: state of the art for diagnosis and treatment. Blood Advances, 2020, 4, 217-217.	2.5	4
174	Vitamin D has no impact on outcomes after HSCT in childrenâ€"A retrospective study. Pediatric Transplantation, 2021, 25, e14008.	0.5	4
175	Musculoskeletal impairments in children receiving intensive therapy for acute leukemia or undergoing hematopoietic stem cell transplant: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2021, 68, e29053.	0.8	4
176	Population Pharmacokinetic Model Development of Tacrolimus in Pediatric and Young Adult Patients Undergoing Hematopoietic Cell Transplantation. Frontiers in Pharmacology, 2021, 12, 750672.	1.6	4
177	Studying the Optimal Intravenous Busulfan Exposure in Pediatric Allogeneic Hematopoietic Cell Transplantation (alloHCT) to Improve Clinical Outcomes: A Multicenter Study. Biology of Blood and Marrow Transplantation, 2015, 21, S102-S103.	2.0	3
178	Poor T Cell Reconstitution at 100 Days after T Cell-Replete Hematopoietic Cell Transplantation (HCT) for SCID Is Associated with Later Risk of Death or Need for 2nd Transplant in the 6901 Prospective Study of the Pidtc. Biology of Blood and Marrow Transplantation, 2016, 22, S101-S102.	2.0	3
179	Acupressure to Reduce Treatment-Related Symptoms for Children With Cancer and Recipients of Hematopoietic Stem Cell Transplant: Protocol for a Randomized Controlled Trial. Global Advances in Health and Medicine, 2019, 8, 216495611987044.	0.7	3
180	Assessment of provider perspectives on otoprotection research for children and adolescents: A Children's Oncology Group Cancer Control and Supportive Care Committee survey. Pediatric Blood and Cancer, 2020, 67, e28647.	0.8	3

#	Article	IF	Citations
181	Transplantation Outcomes for Children with Severe Combined Immune Deficiency (SCID) Have Improved over Time: A 36-Year Summary Report By the Primary Immune Deficiency Treatment Consortium (PIDTC). Biology of Blood and Marrow Transplantation, 2020, 26, S18-S19.	2.0	3
182	Incidence and Outcomes of Patients with Thrombotic Microangiopathy after Transplant: Results of Prospective Screening through a Multi-Institutional Collaborative. Biology of Blood and Marrow Transplantation, 2020, 26, S92.	2.0	3
183	The Relationship Between Busulfan Exposure and Achievement of Sustained Donor Myeloid Chimerism in Patients with Non-Malignant Disorders. Transplantation and Cellular Therapy, 2021, 27, 258.e1-258.e6.	0.6	3
184	Azacitidine Administration Following Hematopoietic Stem Cell Transplantation Is Safe and Feasible in Children with Acute Leukemia. Blood, 2016, 128, 4805-4805.	0.6	3
185	The Beginning of the End of Allogeneic Transplantation for Hurler Syndrome?. New England Journal of Medicine, 2021, 385, 2003-2004.	13.9	3
186	Granulocyte Transfusions in Patients with Chronic Granulomatous Disease Undergoing Hematopoietic Cell Transplantation or Gene Therapy. Journal of Clinical Immunology, 2022, 42, 1026-1035.	2.0	3
187	Optimizing care for GI disorders in children after hematopoietic stem cell transplantation. Gastrointestinal Endoscopy, 2006, 64, 386-388.	0.5	2
188	Early Hematopoietic Cell Transplant (HCT) Outcomes of Children with Severe Combined Immunodeficiency Disease (SCID): The First Seventy Four Patients of the Primary Immune Deficiency Treatment Consortium (PIDTC) Prospective Study 6901. Biology of Blood and Marrow Transplantation, 2015, 21, S289-S291.	2.0	2
189	Musical chairs: in utero HCT via mobilization. Blood, 2016, 128, 2378-2380.	0.6	2
190	Hospital Cost Associated with Veno-Occlusive Disease (VOD) in Patients with Hematopoietic Stem Cell Transplant (HSCT). Biology of Blood and Marrow Transplantation, 2016, 22, S275.	2.0	2
191	Eosinophilic Pustular Folliculitis in Children after Stem Cell Transplantation: An Eruption Distinct from Graftâ€Versusâ€Host Disease. Pediatric Dermatology, 2017, 34, 326-330.	0.5	2
192	Resolution of CGD Related Colitis after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Chronic Granulomatous Diseaseâ€"Early Results From the 6903 Study of the Primary Immune Deficiency Treatment Consortium (PIDTC). Biology of Blood and Marrow Transplantation, 2018, 24, S80-S81.	2.0	2
193	1902. A Survey of Pediatric Bone Marrow Transplant Centers Regarding Local Cytomegalovirus Prophylaxis Management Practices and Interest in a Future Randomized Trial. Open Forum Infectious Diseases, 2018, 5, S546-S547.	0.4	2
194	Effects of Vitamin D Levels on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Children. Biology of Blood and Marrow Transplantation, 2019, 25, S239-S240.	2.0	2
195	Comment on: Olanzapine for chemotherapyâ€induced nausea: Lessons learned from child and adolescent psychiatry. Pediatric Blood and Cancer, 2019, 66, e27456.	0.8	2
196	How We Treat Fever and Hypotension in Pediatric Hematopoietic Cell Transplant Patients. Frontiers in Oncology, 2020, 10, 581447.	1.3	2
197	Unknown cytomegalovirus serostatus in primary immunodeficiency disorders: A new category of transplant recipients. Transplant Infectious Disease, 2021, 23, e13504.	0.7	2
198	A Guidance for Concomitant Drug Reconciliation Prior to Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults. Frontiers in Pediatrics, 2021, 9, 713091.	0.9	2

#	Article	IF	Citations
199	Incidence of Hepatic Veno-Occlusive Disease (VOD) in Premier Healthcare Database. Blood, 2015, 126, 3280-3280.	0.6	2
200	Hematopoietic Cell Transplantation-Comorbidity Index Score Is Correlated with Treatment-Related Mortality and Overall Survival following Second Allogeneic Hematopoietic Cell Transplantation in Children. Transplantation and Cellular Therapy, 2022, 28, 155.e1-155.e8.	0.6	2
201	Feasibility, Safety and Efficacy of Haploidentical Viral Cytotoxic T-Lymphocytes for Children, Adolescents, and Young Adults (CAYA) with Refractory Viral Infections in Primary Immunodeficiencies (PID) Post Solid Organ Transplant (SOT) or Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT). Transplantation and Cellular Therapy, 2022, 28, S106-S107.	0.6	2
202	Reduced Toxicity Myeloablative Conditioning Regimen with Busulfan, Fludarabine and Alemtuzumab for Children withÂNon-Malignant Disorders, Myelodysplastic Syndrome (MDS) and Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2009, 15, 78.	2.0	1
203	Safety, Efficacy, and Favorability of Utilizing Levetiracetam for Busulfan-Induced Seizure Prophylaxis in Pediatric Patients Undergoing Hematopoietic Cell Transplant (HCT). Biology of Blood and Marrow Transplantation, 2013, 19, S257.	2.0	1
204	Sequence of Cyclophosphamide (Cy) and Total Body Irradiation (TBI) Prior to Hematopoietic Cell Transplant (HCT) for Patients with Acute Leukemia: Impact upon Complications and Patient Outcome. Biology of Blood and Marrow Transplantation, 2014, 20, S31-S32.	2.0	1
205	Retrospective Study of 240 Patients with Severe Combined Immunodeficiency Transplanted from 2000-2009: A Report from the Primary Immune Deficiency Treatment Consortium of North America. Biology of Blood and Marrow Transplantation, 2014, 20, S24-S25.	2.0	1
206	Incidence of Hepatic Veno-Occlusive Disease (VOD) in Premier Research Database. Biology of Blood and Marrow Transplantation, 2016, 22, S288-S289.	2.0	1
207	Autoimmune Cytopenias in Pediatric Hematopoietic Cell Transplant (HCT) Patients. Biology of Blood and Marrow Transplantation, 2016, 22, S255.	2.0	1
208	Risk of serious bloodstream infections is low in pediatric hematopoietic stem cell transplant (HSCT) recipients with fevers due to antithymocyte globulins and alemtuzumab. Bone Marrow Transplantation, 2016, 51, 1510-1512.	1.3	1
209	Neurologic-Event-Free Survival (NEFS): A New Endpoint for Severe Combined Immunodeficiency (SCID) Patients Diagnosed by Newborn Screening (NBS) and Treated with Hematopoietic Cell Transplantation (HCT). Biology of Blood and Marrow Transplantation, 2017, 23, S75.	2.0	1
210	Outcome of domino hematopoietic stem cell transplantation in human subjects: An international case series. Journal of Allergy and Clinical Immunology, 2018, 142, 1628-1631.e4.	1.5	1
211	Extended Follow-up After Hematopoietic Cell Transplantation for Î²BÎ± Deficiency with Disseminated Mycobacterium avium Infection. Journal of Clinical Immunology, 2020, 40, 248-250.	2.0	1
212	Third-Party Virus-Specific T-Cell Infusion for Treatment of Refractory Viral Infections: Interim Results from PBMTC SUP1701. Biology of Blood and Marrow Transplantation, 2020, 26, S89-S90.	2.0	1
213	Low T-Cell Receptor Î² ( ) Repertoire Diversity Early Post-Transplant for Severe Combined Immunodeficiency (SCID) Predicts Subsequent Failure of Immune Reconstitution. Biology of Blood and Marrow Transplantation, 2020, 26, S306.	2.0	1
214	Next Generation Sequence Minimal Residual Disease (NGS-MRD) Predicts Event Free Survival (EFS) Irrespective of Hematopoietic Cell Transplantation (HCT) Conditioning Regimen, Graft Î Î² T and B-Cell Depletion or Patient Weight Category in Children with Acute Lymphoblastic Leukemia (ALL). Biology of Blood and Marrow Transplantation, 2020, 26, S90-S92.	2.0	1
215	Reply to Are we certain that chlorhexidine gluconate bathing is not beneficial in deducing central line associated blood stream infections among children with cancer or undergoing hematopoietic stem cell transplantation?. Cancer, 2021, 127, 2813-2814.	2.0	1
216	Hospital Resource Utilization Among Patients With Sickle Cell Disease. Journal of Health Care for the Poor and Underserved, 2003, 14, 122-135.	0.4	1

#	Article	IF	Citations
217	Related and Unrelated Donor Transplantation for Î² Thalassemia Major: Results of an International Survey. Blood, 2018, 132, 308-308.	0.6	1
218	Role of Disease Mechanism in Hematopoietic Cell Transplantation Outcomes for Hemophagocytic Lymphohistiocytosis. Blood, 2019, 134, 3343-3343.	0.6	1
219	Hospital Cost Associated with Veno-Occlusive Disease (VOD) in Patients with Hematopoietic Stem Cell Transplant (HSCT). Blood, 2015, 126, 4452-4452.	0.6	1
220	Antifungal Agents. , 2012, , 1484-1492.e5.		1
221	Comparison of Outcomes for Myeloablative Conditioning Regimens Combining Busulfan with Either Cyclophosphamide or Fludarabine in Children. Blood, 2016, 128, 664-664.	0.6	1
222	Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell Transplantation. Journal of Clinical Pharmacology, 2022, , .	1.0	1
223	Therapyâ€related myeloid neoplasms resembling juvenile myelomonocytic leukemia: a case series and review of the literature. Pediatric Blood and Cancer, 2022, 69, e29499.	0.8	1
224	Megadoses of Haplocompatible Related CD34+ Cells Utilizing Clinimacs-Based Selection With a Fixed CD3+ Dose in Pediatric Patients Is Safe and Effective. Biology of Blood and Marrow Transplantation, 2011, 17, S182.	2.0	0
225	Fludarabine, Busulfan, and Alemtuzumab as a Reduced Toxicity Regimen for Children with Marrow Stem Cell Defects and Malignancy Improves Engraftment and Graft versus Host Disease Without Delaying Immune Reconstitution. Biology of Blood and Marrow Transplantation, 2011, 17, S260-S261.	2.0	0
226	Pre-Allogeneic Hematopoietic Cell Transplant Minimal Residual Disease Predicts Post-Transplant Relapse in Pediatric Acute Myeloblastic Leukemia. Biology of Blood and Marrow Transplantation, 2011, 17, S263.	2.0	0
227	Evaluation of the Utility of Pre-HSCT Brain Mris in Pediatric Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2012, 18, S309.	2.0	0
228	Recovery of Lymphocyte Function May Predict Risk of Leukemic Relapse in Pediatric Patients Undergoing Allogeneic Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2013, 19, S256.	2.0	0
229	Efficacy and Safety of Immunomodulation with Fast Withdrawal of Immunosuppression (FWI) and Donor Lymphocyte Infusions (DLI) for Prevention of Relapse in Children Receiving Allogeneic Hematopoietic Stem Cell Transplant (HCT) for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2013, 19, S325.	2.0	0
230	Plasma and Intracellular Population Pharmacokinetic Analysis of Fludarabine in Pediatric Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients. Biology of Blood and Marrow Transplantation, 2014, 20, S30.	2.0	0
231	Pre-Hematopoietic Cell Transplant (HCT) Disease Status and Early Post-HCT Bone Marrow (BM) Chimerism Remain Predictors of Leukemia Relapse in Children Who Receive Preemptive Post-HCT Immunomodulatory Therapy (IT). Biology of Blood and Marrow Transplantation, 2014, 20, S82-S83.	2.0	0
232	Alemtuzumab Administration in Reduced Toxicity Conditioning (RTC) Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (AlloHCT). What Matters Mostâ€“Timing or Donor Source?. Biology of Blood and Marrow Transplantation, 2015, 21, S209-S210.	2.0	0
233	Serotherapy-Related Fevers, Blood Stream Infections (BSI), and Antibiotic Use in Pediatric Allogeneic Hematopoietic Cell Transplant (HCT) Recipients. Biology of Blood and Marrow Transplantation, 2016, 22, S246-S247.	2.0	0
234	A Study of Impact of Bacterial Blood Stream Infections (BBSI) and Antibiotic Resistance on Transplant Related Mortality (TRM) Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Children: A Multicenter Study. Biology of Blood and Marrow Transplantation, 2016, 22, S259.	2.0	0

#	Article	IF	Citations
235	Plasma and Intracellular Pharmacokinetic (PK) Analysis of Fludarabine in Pediatric Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients. Biology of Blood and Marrow Transplantation, 2016, 22, S253.	2.0	0
236	Late Cardiovascular Morbidity Following Pediatric Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, S60.	2.0	0
237	Evaluation of Preâ€“Hematopoietic Cell Transplantation (HCT) Brain MRI and Neurologic Complications of Pediatric Patients Undergoing HCT for Hematologic Malignancies. Journal of Pediatric Oncology Nursing, 2017, 34, 65-73.	1.5	0
238	Safety of Preemptive Donor Lymphocyte Infusion Based on Mixed Chimerism (MC) in Peripheral Blood or Bone Marrow Subsets in Children Undergoing Hematopoietic Stem Cell Transplant (HSCT) for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2017, 23, S375.	2.0	0
239	Long-Term Treatment Outcome in IPEX Syndrome Patients: An International Multicenter Retrospective Study. Biology of Blood and Marrow Transplantation, 2018, 24, S86-S87.	2.0	0
240	Incidence, Severity, and Duration of Sinusoidal Obstruction Syndrome in High-Risk Neuroblastoma: Contributors, Management, and Outcomes in a Modern Multi-Institutional Cohort. International Journal of Radiation Oncology Biology Physics, 2018, 102, S174.	0.4	0
241	Survival Trends after Allogeneic Hematopoietic Cell Transplant (HCT) in Children Less Than One-Year-Old (Infants). Biology of Blood and Marrow Transplantation, 2018, 24, S116.	2.0	0
242	Improved Mortality Prognostication for Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results From a Virtual Pediatric Systems (VPS) and Center for International Blood and Marrow Transplant Research (CIBMTR) Database Merger. Biology of Blood and Marrow Transplantation, 2018, 24, S117-S119.	2.0	0
243	Myelodysplastic Syndromes and Myeloproliferative Neoplasms in Children. , 2018, , 994-1004.e7.		0
244	The Impact of Total Body Irradiation-Based Regimens on Outcomes in Children and Young Adults with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, S197-S198.	2.0	0
245	Metatranscriptomic Evaluation of Pulmonary Complications after Pediatric Hematopoietic Cell Transplantation Reveals Pathogenic Microbes Linked to Dysregulated Human Immunologic Gene Expression. Biology of Blood and Marrow Transplantation, 2019, 25, S45.	2.0	0
246	Screening and Treatment of Adenovirus Infection in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: Multicenter Survey of Transplant Centers in the United States. Biology of Blood and Marrow Transplantation, 2019, 25, S366-S367.	2.0	0
247	In ALD, I feel the need for speed. Blood, 2019, 133, 1275-1277.	0.6	0
248	Incidence and Cost of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with and without Multi-Organ Dysfunction: Analysis of the Premier Healthcare Database. Biology of Blood and Marrow Transplantation, 2020, 26, S136.	2.0	0
249	Immunologic recovery and basis for infections in the pediatric hematopoietic stem cell transplant recipient. , 2021, , 10-21.e3.		0
250	Antifungal Agents. , 2008, , 1452-1460.		0
251	Delayed Platelet Engraftment and Early Increased Creatinine after Stem Cell Transplant Predicts Sustained Remission in Pediatric Leukemia.. Blood, 2008, 112, 2159-2159.	0.6	0
252	Opportunistic Infections in Pediatric Blood and Marrow Transplantation. Pediatric Oncology, 2014, , 103-131.	0.5	0

#	Article	IF	Citations
253	Risk Factors For Relapse In Children Undergoing Preemptive Immunomodulatory Therapy After Allogeneic Hematopoietic Stem Cell (HSCT) For Acute Leukemia. Blood, 2013, 122, 2082-2082.	0.6	0
254	Risk Factors for Graft Failure with Busulfan/Fludarabine-Based Conditioning in Children Undergoing Allogeneic Hematopoietic Cell Transplantation for Nonmalignant Disorders. Blood, 2014, 124, 1155-1155.	0.6	0
255	Pedigree Analysis Supports a Genotypic-phenotypic Correlation Between an AXIN2 Variant of Unknown Significance and Polyposis/Colorectal Cancer: 2016 ACG Case Reports Journal Award (Trainee): 2016 ACG Presidential Poster Award. American Journal of Gastroenterology, 2016, 111, S683.	0.2	0
256	The Effect of Aging and Pre-Donation Comorbidities on the Related PBSC Donor Experience: A Report from the Related Donor Safety Study (RDSafe). SSRN Electronic Journal, 0, , .	0.4	0
257	Male fertility preservation (FP) at pediatric cancer centers: A report from the Childrenâ€™s Oncology Group (COG).. Journal of Clinical Oncology, 2019, 37, 10050-10050.	0.8	0
258	Female fertility preservation (FP) at pediatric cancer centers: A report from the Childrenâ€™s Oncology Group (COG).. Journal of Clinical Oncology, 2019, 37, 11567-11567.	0.8	0
259	Next Generation Sequence Minimal Residual Disease (NGS-MRD) Predicts Outstanding Event Free Survival (EFS) Regardless of Hematopoietic Cell Transplantation (HCT) Preparative Approach or Graft Alpha/Beta Depletion in Children with Acute Lymphoblastic Leukemia (ALL). Blood, 2019, 134, 4624-4624.	0.6	0
260	Reduced Toxicity Conditioning for Non-Malignant Hematopoietic Cell Transplants. Blood, 2019, 134, 4481-4481.	0.6	0
261	Incidence and Cost of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with and without Multi-Organ Dysfunction: Analysis of the Premier Healthcare Database. Blood, 2019, 134, 4706-4706.	0.6	0
262	Severe, Sudden, Bilateral, Throbbing Headaches in an 11-Year-Old. , 2016, , 353-356.		0
263	Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplant for Hyperinflammatory Inborn Errors of Immunity. Blood, 2020, 136, 36-37.	0.6	0
264	T cell receptor diversity as a biomarker for immune reconstitution after bone marrow transplantation for Severe Combined Immunodeficiency. Journal of Allergy and Clinical Immunology, 2022, 149, AB225.	1.5	0
265	Hematopoietic Cell Transplantation in 240 Patients with Chronic Granulomatous Disease: A Pidtc Report. Transplantation and Cellular Therapy, 2022, 28, S101-S103.	0.6	0
266	A Primary Immune Deficiency Treatment Consortium (PIDTC) Study of Chronic and Late Onset Medical Complications after Initial Hematopoietic Cell Transplantation (HCT) for Severe Combined Immunodeficiency Disease (SCID). Transplantation and Cellular Therapy, 2022, 28, S339-S340.	0.6	0
267	Outcomes after Hematopoietic Cell Transplant and Gene Therapy for Adenosine Deaminase (ADA) Severe Combined Immune Deficiency: A Combined Analysis from the Primary Immune Deficiency Treatment Consortium (PIDTC) 6901 and 6902 Studies. Transplantation and Cellular Therapy, 2022, 28, S100-S101.	0.6	0